Insmed, Inc. (NASDAQ:INSM - Get Free Report) CEO William Lewis sold 10,699 shares of the stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $150.97, for a total transaction of $1,615,228.03. Following the sale, the chief executive officer directly owned 301,185 shares of the company's stock, valued at $45,469,899.45. This represents a 3.43% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.
William Lewis also recently made the following trade(s):
- On Monday, February 9th, William Lewis sold 13,396 shares of Insmed stock. The stock was sold at an average price of $147.79, for a total transaction of $1,979,794.84.
- On Tuesday, February 3rd, William Lewis sold 3,009 shares of Insmed stock. The shares were sold at an average price of $156.34, for a total transaction of $470,427.06.
- On Tuesday, January 20th, William Lewis sold 10,699 shares of Insmed stock. The stock was sold at an average price of $158.93, for a total transaction of $1,700,392.07.
- On Monday, January 12th, William Lewis sold 19,215 shares of Insmed stock. The stock was sold at an average price of $169.00, for a total transaction of $3,247,335.00.
- On Thursday, January 8th, William Lewis sold 3,223 shares of Insmed stock. The shares were sold at an average price of $174.17, for a total transaction of $561,349.91.
- On Wednesday, January 7th, William Lewis sold 2,357 shares of Insmed stock. The shares were sold at an average price of $175.07, for a total transaction of $412,639.99.
- On Tuesday, January 6th, William Lewis sold 4,096 shares of Insmed stock. The stock was sold at an average price of $173.33, for a total value of $709,959.68.
- On Thursday, December 18th, William Lewis sold 10,699 shares of Insmed stock. The shares were sold at an average price of $166.97, for a total value of $1,786,412.03.
Insmed Stock Down 3.6%
Shares of Insmed stock opened at $159.03 on Tuesday. The stock's 50-day moving average is $164.37 and its 200 day moving average is $164.24. Insmed, Inc. has a one year low of $60.40 and a one year high of $212.75. The firm has a market cap of $34.28 billion, a price-to-earnings ratio of -24.81 and a beta of 1.11. The company has a debt-to-equity ratio of 0.76, a current ratio of 3.83 and a quick ratio of 3.54.
Insmed (NASDAQ:INSM - Get Free Report) last issued its quarterly earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.07) by ($0.47). The business had revenue of $263.84 million during the quarter, compared to analyst estimates of $263.97 million. Insmed had a negative net margin of 210.54% and a negative return on equity of 168.36%. Insmed's quarterly revenue was up 152.6% compared to the same quarter last year. During the same period last year, the firm posted ($1.32) earnings per share. Equities research analysts anticipate that Insmed, Inc. will post -4.56 EPS for the current year.
Wall Street Analyst Weigh In
Several research firms have weighed in on INSM. The Goldman Sachs Group lifted their price target on shares of Insmed from $225.00 to $258.00 and gave the company a "buy" rating in a research note on Monday, December 15th. Weiss Ratings restated a "sell (d-)" rating on shares of Insmed in a research note on Thursday, January 22nd. Roth Mkm raised Insmed to a "strong-buy" rating in a research report on Friday, January 23rd. Bank of America set a $203.00 price target on Insmed in a report on Thursday, December 18th. Finally, Truist Financial set a $205.00 price objective on Insmed in a research note on Monday, January 12th. Three research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $207.86.
Read Our Latest Stock Report on INSM
Institutional Investors Weigh In On Insmed
A number of institutional investors have recently added to or reduced their stakes in INSM. CIBC Private Wealth Group LLC lifted its position in shares of Insmed by 42.1% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company's stock worth $26,000 after buying an additional 53 shares in the last quarter. CoreCap Advisors LLC purchased a new stake in shares of Insmed during the fourth quarter valued at approximately $27,000. Stone House Investment Management LLC bought a new stake in Insmed during the third quarter worth $29,000. SBI Securities Co. Ltd. boosted its position in Insmed by 404.9% in the third quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company's stock worth $30,000 after purchasing an additional 166 shares during the last quarter. Finally, GraniteShares Advisors LLC purchased a new position in Insmed in the fourth quarter worth $30,000.
Insmed Company Profile
(
Get Free Report)
Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.
The company's principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
